GlobalData on MSN15h
JP Morgan 2025: Novartis streamlines its portfolio to drive future growth
Eight blockbuster drugs are expected to generate over $3bn in peak sales each according to Novartis CEO Vas Narasimhan.
GlobalData on MSN1d
JP Morgan 2025: Dexcom shares up 5% after 2025 outlook forecasts $4.6bn in revenue
Buoyed by the recent launch of Stelo and further upcoming CGM launches, Dexcom is anticipating a 14% growth in 2025 over 2024 ...
Pensions&Investments1h
JP Morgan’s asset and wealth management AUM hits $4 trillion; Dimon cautions on inflation.
J.P. Morgan Chase’s asset and wealth management division reported assets under management of $4 trillion as of Dec. 31, up 18 ...
XRP Price Eyes 30% Rally in January Following JP Morgan’s Bullish Outlook
XRP targets a 30% rally by January’s end, driven by ETF speculation, whale accumulation, and a bullish breakout. SEC ...
24/7 Wall St. on MSN6d
JP Morgan’s Best 2025 Stock Ideas Include 5 Blue-Chip Dividend Giants
The research team at J.P. Morgan is out with the firm's 2025 Year Ahead Best Idea list, and we found five companies that look ...
decrypt16h
Solana and XRP ETFs Could Attract Billions, But Will Fall Short of Bitcoin: JP Morgan
Expected Solana and XRP ETFs could attract sizable investment, JP Morgan analysts said, but it's unlikely they'll match the ...
Pharmaceutical Technology6h
JP Morgan 2025: Almirall updates strategy with focus on medical dermatology
Spain’s Almirall has announced strategic plans at the 43rd JP Morgan Healthcare Conference based on expected double-digit growth within the dermatological area for Almirall’s psoriasis and atopic ...
Irish Daily Mirror8d
The reason JP McManus had to spend big on The New Lion ahead of the Cheltenham Festival
JP McManus stunned the racing world on Saturday by splashing the cash to purchase exciting novice hurdler The New Lion. The ...